Summary
To preliminarily determine the appropriate dosage of carboplatin (CBP) at AUC of 5 mg·Ml−1·min−1 in the combination chemotherapy for Chinese senile patients with non-small cell lung cancer (NSCLC). Thirty-five Chinese senile patients with NSCLC in advanced stage (III/IV) were given 96 cycles of combination chemotherapy. Chemotherapy schedules included Taxol+CBP, Gemzar+CBP and NVB+CBP. The dose of CBP was at 5 mg·mL−1·min−1 of area under the concentration-time curve (AUC). Side effects and quality of life were observed before and after the chemotherapy. Myelosuppression was severe and commonly observed. Grade 3/4 of granulocytopenia was found in 47.9% (46/96) of the patients and grade 3/4 of thrombocytopenia was noted in 28.1% (27/96) of the subjects. However, other side effects were slight. The mean score of quality of life (QOL), according to the criteria of QOL for Chinese cancer patients had reduced 6.8. At 5 mg·mL−1·min−1 by AUC, the hematological toxicity of CBP was severe and it had some negative effects on the QOL. The administration of CBP at 5 mg·mL−1·min−1 by AUC may be too high for Chinese senile patients with non-small cell lung cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sun Y. Scoring of Quality of Life in Tumor Patients. In: Sun Y, Zhou J C. Manual of Clinical Oncology (Chinese). Beijing: People’s Health Publishing House, 1996.53
Non Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J, 1995,1(1):899–909
Sweeney C J, Zhu J, Sandler A B et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594. Cancer, 2001,15:2639–2647
Zatloukal P, Petruzelka L. Gemcitabine/carbopltin in advanced non-small cell lung cancer. Lung Cancer, 2002,38(Suppl 2):S33–S36
Paccagnella A, Favaretto A, Oniga F et al. Cisplatin versus carboplatin in combination with mitomycin and inblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer, 2004,43,83–91
Schiller J H, Harrington D, Belani C P et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med, 2002,346:92–98
Jelic S, Mitrovic L, Radosavljevic D et al. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study. Lung Cancer, 2001,34:1–13
CHU Q, Vincent M, Logan D et al. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer, 2005,50(3):355–374
Sculier J P, Paesmans M, Thiriaux J et al. A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. Eur J Cancer, 1999,35:1314–1319
CHU D T, LUO Y, LI J L et al. The efficacy and toxicity of carboplatin in AUC dosing in treatment of small-cell lung cancer. Chinese J Clinical Oncology, 2001,28(1):28–30
Okamoto H, Nagatomo A, Kunitoh H et al. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae. Cancer Chemother Pharmacol, 1998,42:307–312
Martin D A, James O A, Allen S L et al. Clinical Oncology. 2nd ed. Beijing: Science Press, 2001.385
Author information
Authors and Affiliations
Corresponding author
Additional information
This project was supported by a grant from a key research program of the Education Bureau of Hubei Province (D2006-02-002).
Rights and permissions
About this article
Cite this article
Yin, T., Liu, Q., Hu, C. et al. Determination of carboplatin dose by area under the curve in combination chemotherapy for senile non-small cell lung cancer. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 27, 710–712 (2007). https://doi.org/10.1007/s11596-007-0624-x
Received:
Issue Date:
DOI: https://doi.org/10.1007/s11596-007-0624-x